Despite assurances that there was sufficient stock of Jext autoinjectors, there is now a supply shortage. The alert below has been provided by the medicines optimisation team to deal with this short term problem.
ALERT
November 2013
Jext® 300microgram Adrenaline Auto-injector
Background:
ALK-Abelló Ltd have made us aware aware of a shortage of Jext 300microgram adrenaline auto-injectors. The shortage may last until mid-December, but will hopefully be resolved sooner.
The shortage has been caused by a much higher than expected prescription rate in the UK in September, coupled with the adoption of Jext in France, to replace Anapen. In order to maximise shelf-life of the devices in patients’ hands, ALK have minimised stockholding in the UK, so there is very little buffer stock in the supply chain. ALK have assured us that they are making every effort to resolve the issue, and understand the difficulty that this causes at a crucial stage in the roll-out of the change from Epipen to Jext.
Action Required:
GPs should prescribe Epipen in the equivalent dose on a temporary basis only until ALK confirm that stocks are again available. The patient will then keep the Epipen until expiry and will receive Jext (with training) at the next renewal.
Community Pharmacies should request the patients GP prescribes Epipen in the equivalent dose if they are unable to obtain supplies of Jext.
It is essential that whichever auto-injector is supplied, device-specific training should be provided.
Further Information:
Your practice pharmacist may be able to advise on action for individual patients
Alternatively contact your locality Medicines Optimisation Pharmacist on
0191 217 2858 or Marie Thompkins NECS MO contact for this initiative[email protected]
ALK customer services stock availability: 0118 903 7940.
ALK locality contact Shona Hawkins : 07917 631740
November 2013
Jext® 300microgram Adrenaline Auto-injector
Background:
ALK-Abelló Ltd have made us aware aware of a shortage of Jext 300microgram adrenaline auto-injectors. The shortage may last until mid-December, but will hopefully be resolved sooner.
The shortage has been caused by a much higher than expected prescription rate in the UK in September, coupled with the adoption of Jext in France, to replace Anapen. In order to maximise shelf-life of the devices in patients’ hands, ALK have minimised stockholding in the UK, so there is very little buffer stock in the supply chain. ALK have assured us that they are making every effort to resolve the issue, and understand the difficulty that this causes at a crucial stage in the roll-out of the change from Epipen to Jext.
Action Required:
GPs should prescribe Epipen in the equivalent dose on a temporary basis only until ALK confirm that stocks are again available. The patient will then keep the Epipen until expiry and will receive Jext (with training) at the next renewal.
Community Pharmacies should request the patients GP prescribes Epipen in the equivalent dose if they are unable to obtain supplies of Jext.
It is essential that whichever auto-injector is supplied, device-specific training should be provided.
Further Information:
Your practice pharmacist may be able to advise on action for individual patients
Alternatively contact your locality Medicines Optimisation Pharmacist on
0191 217 2858 or Marie Thompkins NECS MO contact for this initiative[email protected]
ALK customer services stock availability: 0118 903 7940.
ALK locality contact Shona Hawkins : 07917 631740
RSS Feed
